Zeltia SA : Pivotal Phase III Patient Recruitment of YONDELIS® Trial (SAR-3007) in Leiomyosarcoma and Liposarcoma Completed

Pivotal Phase III Patient Recruitment of YONDELIS® Trial (SAR-3007) in Leiomyosarcoma and Liposarcoma Completed

The trial will evaluate the efficacy of Yondelis® versus dacarbazine in the treatment of Leiomyosarcoma and Liposarcoma (L-type Sarcomas)

Madrid, 18th. December 2013.-PharmaMar, an oncology focused subsidiary of Zeltia (MEC: ZEL), today announced that Janssen Research & Development, LLC, has completed patient recruitment for SAR-3007,a registration Phase III study of YONDELIS® for the treatment of L- type sarcomas.

SAR-3007 is a pivotal, randomized (2:1), controlled, multicenter study comparing the safety and efficacy of YONDELIS® versus dacarbazine for the treatment of advanced or metastatic L-type sarcomas previously treated with an anthracycline and ifosfamide, or an anthracycline followed by one additional line of chemotherapy.

In Europe and other non-US countries, YONDELIS® is approved for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide or patients who are not suitable for treatment with these agents. YONDELIS® is also approved, in combination with pegylated liposomal doxorubicin, for the treatment of platinum-sensitive recurrent ovarian cancer.

About PharmaMar
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based antitumour drug. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184.
PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

1

About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world- leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading company in molecular diagnostics based on DNA analysis; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).
Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Zeltia, S.A. (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.
For more information +34 91 444 4500
This note is also available on the PharmaMar web site: www.pharmamar.comand at Zeltia's website:
www.zeltia.com

2

distributed by